Your browser doesn't support javascript.
loading
Impact of prior cancer history on survival in brain malignancy: A propensity score-adjusted, population-based study.
Ebad Ur Rehman, Mohammad; Faraz, Fatima; Cheema, Huzaifa Ahmad; Ashruf, Omer S; Raheel, Hamna; Naqvi, Syeda Zainab Ali; Jabeen, Nimrah; Abid, Areesha; Mumtaz Malik, Haris; Iftikhar, Ahmad; Ibrahim, Ahmed; Swed, Sarya.
Afiliación
  • Ebad Ur Rehman M; Department of Medicine, Rawalpindi Medical University, Rawalpindi, Pakistan.
  • Faraz F; Department of Medicine, Rawalpindi Medical University, Rawalpindi, Pakistan.
  • Cheema HA; Department of Medicine, King Edward Medical University, Lahore, Pakistan.
  • Ashruf OS; Department of Internal Medicine, Northeast Ohio Medical University, Rootstown, Ohio, USA.
  • Raheel H; Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
  • Naqvi SZA; Department of Medicine, Rawalpindi Medical University, Rawalpindi, Pakistan.
  • Jabeen N; Department of Medicine, Rawalpindi Medical University, Rawalpindi, Pakistan.
  • Abid A; Department of Medicine, Rawalpindi Medical University, Rawalpindi, Pakistan.
  • Mumtaz Malik H; Department of Medicine, Rawalpindi Medical University, Rawalpindi, Pakistan.
  • Iftikhar A; Department of Medicine, The University of Arizona, Tucson, Arizona, USA.
  • Ibrahim A; Rawalpindi Medical University, Rawalpindi, Pakistan.
  • Swed S; Faculty of Medicine, University of Aleppo, Aleppo, Syria.
Cancer Rep (Hoboken) ; 7(2): e1984, 2024 02.
Article en En | MEDLINE | ID: mdl-38389401
ABSTRACT

BACKGROUND:

Individuals with a Prior Cancer History (PCH) are often excluded from clinical trials. However, a growing body of evidence suggests that prior cancer history does not present adverse outcomes on cancer patients. The evidence on the survival of brain cancer patients in this regard remains widely unknown.

METHODS:

We conducted a retrospective cohort study to estimate the prevalence and impact of prior cancer on survival of patients diagnosed with brain cancer. Data of patients who were diagnosed with brain cancer as their first or second primary malignancy between 2000 and 2019 were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. Propensity Score Matching (PSM) was used to ensure comparable baseline characteristics among the patients. Survival analysis was conducted using the Kaplan-Meier method, as well as multivariate Cox proportional hazard and multivariate competing risk models.

RESULTS:

Out of 42 726 patients, 1189 (2.78%) had PCH. Genitourinary (40.4%), Breast (13.6%), Hematologic and Lymphatic (11.4%), and Gastrointestinal malignancies (11.3%) were the most common types of prior cancer. PCH served as a significant risk factor for Overall Survival (OS) (Adjusted Hazard Ratio [AHR] 1.26; 95% CI [1.15-1.39]; p < .001) but did not have a statistically significant impact on Brain Cancer-Specific Survival (BCSS) (AHR 0.97; 95% CI [0.88-1.07]; p = .54). Glioblastoma exhibited the most substantial and statistically significant impact on survival as compared to other histological types. Of all the organs systems, only prior Gastrointestinal and Hematologic and Lymphatic malignancies had a statistically significant impact on OS of patients.

CONCLUSION:

Our findings indicate that PCH does not exert a substantial impact on the survival of brain cancer patients, except in cases involving gastrointestinal or hematologic and lymphatic PCH, or when the brain cancer is glioblastoma.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias Encefálicas / Neoplasias Primarias Secundarias / Glioblastoma Límite: Humans Idioma: En Revista: Cancer Rep (Hoboken) Año: 2024 Tipo del documento: Article País de afiliación: Pakistán

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias Encefálicas / Neoplasias Primarias Secundarias / Glioblastoma Límite: Humans Idioma: En Revista: Cancer Rep (Hoboken) Año: 2024 Tipo del documento: Article País de afiliación: Pakistán